Matches in Nanopublications for { ?s ?p "[In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP1266985.RAXYGkdXPRCPvCpYW_hSLS5doF-lYvm49Hvjepillx5gE130_assertion description "[In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266985.RAXYGkdXPRCPvCpYW_hSLS5doF-lYvm49Hvjepillx5gE130_provenance.
- NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_assertion description "[In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by the United States Food and Drug Administration for use in advanced ovarian cancer patients with germline BRCA1/2 mutations who have received three or more prior lines of chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266983.RA8mzamYRzHp77amrz_P99IrjKC5AoGsMPVZc2dAPCQiI130_provenance.